针对瘤向的化学光动力学疗法的光共价有机框架的合成
Mahsa Nazari1, Mina Alikhani2, Sirous Nekooei3
1Department of Chemistry, Faculty of Science, Ferdowsi University of Mashhad, Mashhad, Iran.
International journal of pharmaceutics
|April 20, 2025
概括
这项研究介绍了一种使用装饰的氨酸基共价有机框架 (pCOF-I) 进行黑色素瘤治疗的新型化纳米平台. 该平台可以将光动力学疗法,化疗和计算机断层扫描成像用于向癌症治疗.
科学领域:
- 纳米医学是一种纳米医学.
- 材料科学 材料科学 材料科学
- 生物医学工程 生物医学工程
背景情况:
- 共价有机框架 (COFs) 正在成为纳米医学的有前途的纳米载体.
- 需要先进的治疗神经系统平台来有效治疗癌症,特别是黑色素瘤.
- 结合多种治疗和诊断方式,为癌症治疗提供了一种协同的方法.
研究的目的:
- 开发一种用于治疗黑色素瘤的新型神经感应纳米平台.
- 为了整合光动力疗法 (PDT),化疗 (多克索鲁比辛封装) 和计算机断层扫描 (CT) 成像.
- 为了实现有针对性的输送和增强的治疗疗效,使用AS1411的aptamer向系统.
主要方法:
- 以联体 (pCOF-I) 装饰的基于氨酸的共价有机框架的合成.
- 用COOH-PEG-NH2对多克索鲁比 (DOX) 进行封装和表面修饰,用于AS1411的阿帕特马结合.
- 在体外和体外对药物释放,细胞吸收,细胞毒性,PDT疗效和CT成像的评估.
主要成果:
- 成功合成了带有控制的DOX释放的中孔性pCOF-I纳米平台.
- 在体外和体内证明了联合化疗-PDT对B16F0黑色素瘤细胞的疗效.
- 目标平台显示较高的细胞吸收和毒性;实现了有效的瘤CT成像.
结论:
- AS1411的向阿巴体的pCOF-I系统是CT成像导向化疗PDT的开创性治疗平台.
- 这种多模式的方法显著提高了黑色素瘤治疗的治疗结果.
- 开发的纳米平台代表了多模式癌症治疗策略的重大进步.
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Tumor Immunotherapy
401
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
401


